James Davis, PharmD, BCOP

Malignant hematology pharmacist and affiliate assistant professor @MUSCHollings #lymphoma #myeloma opinions are my own

[James Davis, PharmD, BCOP @thisisJamesD]

@RahulBanerjeeMD @fredhutch @UWMedicine well deserved, congrats my friend!

[James Davis, PharmD, BCOP @thisisJamesD]

💡 🧠 Hot off the press in its entirety... Our multi-center study looking into the safety of MMR vaccination in patients with myeloma receiving daratumumab maintenance after ASCT! Out now in @BloodPortfolio #BloodNeoplasia https://t.co/pOY7cJCQFD

[James Davis, PharmD, BCOP @thisisJamesD]

a couple of our research projects (CMV reactivation and MMR with daratumumab) made John's #HOPA26 recap. check it out the @OncoPharmPod podcast here... https://t.co/SxTDwfMuXs @PharmDeetinib @kczmj @j_snyder0132 @VictoriaNachar @KG_PharmD @Warrick_PharmD

[Hamza Hashmi @hhashmi87]

Efficacy of Stem Cell Boost (SCB) for CAR-T-related hematologic toxicity in #RRMM-RWE from the US multiple myeloma immunotherapy consortium
https://t.co/pIwiTLGBFt
Fortunate to have played a small part in this tremendous effort by #CindyVarga 👏🙌🎆
#MMSM #Medtwitter @BloodCancerJnl
@thisisJamesD @khouri_jack @ForsbergMD @AimazAfrough @ldandersonjr @leshune @TomBmt133 #DorisHansen & many more

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Analysis from US Multiple Myeloma Immunotherapy Consortium of real-world elranatamab data finds median PFS & OS 4.3 & 14.6 mos; elevated LDH & low Hgb predict poor outcomes; prior BCMA exposure reduced response depth: https://t.co/cWilnMWaAI. #mmsm

[PeerView @PeerView]

Join Amir Ali, PharmD, BCOP, and James Davis, PharmD, BCOP (@ThisisJamesD) on 4/2 at 7 PM EDT for a #BispecificAntibodies in #Lymphoma #MedEd virtual event: https://t.co/QYJtT1j9I7

[Andrew Portuguese, MD @AJPortuguese]

Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. https://t.co/TNHq2yGj7V

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time.

"Can I get MMR 💉 on dara-len maintenance?"

Short answer: 💯%, it seems!

Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!

[PeerView @PeerView]

Pharmacist Leadership for #Lymphoma Care: Apply real-world case insights to support pharmacist decision-making with #BispecificAntibodies. Join Amir Ali, PharmD, BCOP, and James Davis, PharmD, BCOP (@ThisisJamesD), on 4/2 at 7 PM EDT for a virtual event: https://t.co/QYJtT1j9I7

[James Davis, PharmD, BCOP @thisisJamesD]

Great article by @RahulBanerjeeMD @Bethfaiman et al reviewing the history and role of dexamethasone in plasma cell disorders. further solidifying the mantras #downwithdex and #DownWithDexExceptForCRS
https://t.co/hiKslRdYhL

[James Davis, PharmD, BCOP @thisisJamesD]

@DrGarethMorgan1 @Bethfaiman I saw the poster too and thought this Sankey diagram must have been a nightmare to create

[Dae Hyun Lee MD @daehyunleemd]

#ASH25 Come swing by our poster #4066. We show the incidence, risk factor and outcome of CV events during teclistamab in a multicenter registry! #USMMITC @MoffittNews @PennCardiology @PennCancer @md_addison @RahulBanerjeeMD @thisisJamesD amongst many others!

[James Davis, PharmD, BCOP @thisisJamesD]

Earlier in the year we published efficacy of #pocketdex in patients receiving teclistamab, Sunday we present our group’s second pharmD led oral abstract at #ASH25 validating the safety of dex with talquetmab. Again, you don’t need toci for low grade CRS! https://t.co/yh4ZBclxwP

[James Davis, PharmD, BCOP @thisisJamesD]

https://t.co/tqi0qLWmvu

[James Davis, PharmD, BCOP @thisisJamesD]

Getting excited to present our multi-center oral abstract at #ASH25 Saturday at 5:15pm investigating safety of MMR vaccines in patients on dara maintenance @kczmj @VictoriaNachar @KLratermann @AMDominickDO @KG_PharmD

[Vincent Rajkumar @VincentRK]

#5 Stem cell boost as treatment for cytopenias after CART. Cindy Varga et al. @SurbhiSidanaMD @hhashmi87 @TomBmt133

Highly effective, safe, and practical. #ASH25

Link: https://t.co/NUEULf9raW

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/1/25 v2 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren

[AmericanJournalofHematology @AjHematology]

For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology.
https://t.co/aV2rpKDtgI
@AlGarfall

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Real-world study of bispecific T-cell engager safety & efficacy in systemic AL #amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac & renal response in 64% & 100%; CRS in 45% (all G 1/2): https://t.co/LRNoCnjUD7. #mmsm

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Dex for management of CRS assoc w/ talquetamab [GPRC5D-targeting bispecific antibody (bsAb)] in Pts w/ RRMM [Nov 3, 2025] McElwee et al. #ASH25 abs25-14627 PID 720
https://t.co/L0BCnUjue9 #mmsm #SuppOnc